These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18325740)

  • 1. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.
    Bora E; Veznedaroğlu B; Kayahan B
    Clin Neuropharmacol; 2005; 28(3):139-41. PubMed ID: 15965314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
    Schubert MH; Young KA; Hicks PB
    Biol Psychiatry; 2006 Sep; 60(6):530-3. PubMed ID: 16806095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?
    Norén U; Björner A; Sonesson O; Eriksson L
    Schizophr Res; 2006 Jul; 85(1-3):302-4. PubMed ID: 16675200
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
    Rosse RB; Deutsch SI
    Clin Neuropharmacol; 2002; 25(5):272-5. PubMed ID: 12410061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.
    Barr RS; Culhane MA; Jubelt LE; Mufti RS; Dyer MA; Weiss AP; Deckersbach T; Kelly JF; Freudenreich O; Goff DC; Evins AE
    Neuropsychopharmacology; 2008 Feb; 33(3):480-90. PubMed ID: 17443126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
    Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
    Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
    Voss B; Thienel R; Leucht S; Kircher T
    Nervenarzt; 2008 Jan; 79(1):47-8, 50-2, 54-9. PubMed ID: 17960354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
    Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
    CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
    Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.
    Roh S; Hoeppner SS; Schoenfeld D; Fullerton CA; Stoeckel LE; Evins AE
    Psychopharmacology (Berl); 2014 Feb; 231(4):765-75. PubMed ID: 24114425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.
    Koontz J; Baskys A
    Am J Alzheimers Dis Other Demen; 2005; 20(5):295-302. PubMed ID: 16273995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.
    Sacco KA; Creeden C; Reutenauer EL; George TP
    Schizophr Res; 2008 Aug; 103(1-3):326-7. PubMed ID: 18571377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.